Our Mission, Our Story

Our Mission

Create a new standard of care for a large spectrum of heart failure patients by introducing breakthrough implantable circulatory support solutions that restore a normal life with minimal side effects.

Our Story

CorWave is a high-growth company incorporated in 2012 by the startup studio MD Start and supported by renowned investors. We raised more than 35 million euros in funding, and the company employs more than 50 people. Since its creation, the company has won numerous awards and competitions.

1996

Invention of wave membrane technology by Jean-Baptiste Drevet, he collaborates with the CNRS and creates AMS R&D

2012

Creation of the company CorWave by the startup studio MD Start and exclusive license agreement with AMS R&D

2012

CorWave joins Agoranov Incubator

2013

€ 3.3M in Series A financing raised from Bpifrance, Seventure and Sofinnova

First presentation at a scientific congress of cardiac surgery

2014

CorWave joins Paris Biotech Santé incubator

2016

Participates in the Worldwide Innovation Challenge, wins phase 1 for the NovaPulse project (Nemo development)

€15.5M in series B financing raised from Novo Seeds, Ysios Capital and existing investors

2017

Participates in the Worldwide Innovation Challenge, wins phase 2 for the NovaPulse project

Receives the Deloitte Technology Fast 50 Biotech Future award

CorWave sets up its current 1,300 m² facility near Paris, with laboratories and a pilot production unit

2018

Nominated for “Trophée des Futures Licornes”  award

Receives a PSPC grant by BPI for the Calypso project, in partnership with Lille University Hospital and AP-HP-Pitié Salpêtrière Hospital

First patent granted in the US

2019

Performs a successful chronic preclinical study

Selected among KPMG Tech Pulse 40 companies

Receives “Trophée de l’embarqué” award for healthcare category

2020

Receives an EIC Accelerator grant from the European Commission

Selected as a Showcase Company by Medtech Innovator

2021

€35M in series C financing raised from historic investors joined by the EIC Fund and Financière Arbevel 

CorWave is part of the French Tech 120 index, a selection of 120 French startups and scaleups with the potential to become global technology leaders


    CorWave is part of the French Tech 120 index, a selection of 120 French startups and scaleups with the potential to become global technology leaders.

     


      This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954151.

       


        CorWave’s Industrialization program is supported by the Paris region through the call for projects “Relance Industrie”.

         


          CorWave’s R&D program is supported by the French state through the “Programme d’Investissements d’Avenir” (PIA).

           

            Lille University Hospital and the Pitié-Salpêtrière Hospital (AP-HP) are CorWave’s partners within this R&D program.

            We have over 50 employees, hailing from around the globe.